6th Annual MarketsandMarkets

Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)

12th - 14th October 2021

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

The 6th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference scheduled to be held from 12th - 15th October 2021 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Online Registration

 10:30 - 10:50

Welcome note from MarketsandMarkets

 10:50 - 10:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

 10:55 - 11:00

Keynote Presentation: Leveraging Translational Precision Medicine To Accelerate Discoveries Towards Better Health

Pallavi Sachdev

Pallavi Sachdev , Senior Director, Clinical Pharmacology and Translational Medicine , Eisai

 11:00 - 11:30

BIOMARKERS IN CLINICAL & TRANSLATIONAL DEVELOPMENT: DRUG DISCOVERY AND ASSAY DEVELOPMENT

Non-invasive Biomarker Discovery and Analysis from Exhaled Breath

 11:30 - 12:00

SafeSEQ ultra-sensitive ctDNA technology

Hillary Sloane

Hillary Sloane, Associate Director, Medical Scientific Affairs, Sysmex Inostics

 12:00 - 12:30

Slide-Based Multiplexing Biomarker Assays for Companion Diagnostics

 12:30 - 13:00

Networking and One-on-One Meetings on the event portal

 13:00 - 13:15

A novel empirical process for setting true assay QC specifications

Jim Garrett

Jim Garrett, Senior Associate Director Biostatistics, Novartis

 13:15 - 13:45

Informed by the tumor: the power of a personalized ctDNA assay

 13:45 - 14:15

Navigating Speedbumps on the Road to CDx Approval and Commercialization

James Yen

James Yen, Associate Director, CDx Strategy, , NeoGenomics

 14:15 - 14:45

Clinical implementation of SMRT sequencing for Precision Medicine in Immune diseases

 14:45 - 15:15

Closing Remarks from the Chairman

 15:15 - 15:20

Networking and One-on-One Meetings

 15:20 - 16:20

Online Registration

 10:30 - 10:50

Welcome note from MarketsandMarkets

 10:50 - 10:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

 10:55 - 11:00

Keynote Presentation: Progressing precision medicine in the non-oncology space

Maria Orr

Maria Orr, Head of Precision Medicine, AstraZeneca

11:00 - 11:30

INNOVATIONS IN BIOMARKER RESEARCH: DIGITAL BIOMARKERS AND PREDICTIVE BIOMARKERS

Clinical applications of Liquid Biopsy- An overview

 11:30 - 12:00

Neoantigen Targeted Cancer Immunotherapy in the Clinic

Matt Davis

Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

12:00 - 12:30

Beyond the Flat Genome: 3D Genomics Yields Novel Biomarkers for Therapeutics and Diagnostics

Ibrahim Jivanjee

Ibrahim Jivanjee, Director of Product Management and Marketing, Arima Genomics

 12:30 - 13:00

Networking and One-on-One Meetings on the event portal

 13:00 - 13:15

Development and Delivery of Multiplexed Protein Biomarker Tests to to Address Key Unmet Clinical Needs

Stephen Pennington

Stephen Pennington, Professor, Proteomics, University College Dublin

 13:15 - 13:45

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Jessica McDonough

Jessica McDonough, Co-Founder, Attivare Therapeutics

 13:45 - 14:15

X-Omics Platform: A validated platform for multi-omics data analysis

Stefan Pinkert

Stefan Pinkert, Principal Scientist, Oncology Bioinformatics, Merck

 14:15 - 14:45

Measurement Methods and Standards for DNA Damage in Mammalian Cells

Donald Atha

Donald Atha, Research Chemist, National Institute of Standards and Technology (NIST)

14:45 - 15:15

Big questions with simple solutions: Spatial Biology in a few automated steps

Barbara Cahill

Barbara Cahill, Sr. Global Portfolio Manager for Immunohistochemistry, Consumables and Cytology, , Epredia

 15:15 - 15:45

Biology-Inspired Intelligence | an emerging model of precision medicine for the brain and mind

George Pell

George Pell, CEO and Founder, Thirty-Six

 15:45 - 16:15

Closing remarks from the Chairman

 16:15 - 16:20

Networking and One-on-One Meetings

 16:20 - 17:00

Online Registration

 10:30 - 10:50

Welcome note from MarketsandMarkets

10:50 - 10:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

 10:55 - 11:00

Keynote Presentation: Novel Safety Biomarker Implementation: Exploration to Regulatory Qualification

Shashi Ramaiah

Shashi Ramaiah, Head, Safety Biomarkers, Translational Sciences, Pfizer

 11:00 - 11:30

IMMUNO-ONCOLOGY BIOMARKERS & DESIGN OF CLINICAL TRIALS IN CDX

Transforming Global Clinical Trials with Liquid Biopsy and CDx Solutions

Reed Selby

Reed Selby, Director of Biopharma Business Development, Predicine

 11:30 - 12:00

Quantifying receptor occupancy by ligand using RNA aptamers: A potential biomarker for predicting efficacy of immune checkpoints and beyond

George Weiner

George Weiner, Oncologist, University of Iowa

 12:00 - 12:30

VHH single domain antibodies as a diagnostic tool for in vivo and ex vivo biomarker assessment

Marion Cubitt

Marion Cubitt, Associate Director, Isogenica

 12:30 - 13:00

Networking and One-on-One Meetings on the event portal

 13:00 - 13:15

Biomarker strategy for pan FGFR inhibitor Rogaratinib

Yinghui Zhou

Yinghui Zhou, Senior Director, Translational Strategy, Bayer

13:15 - 13:45

Local delivery of anti-PD L1 nanobodies overcomes poor antibody penetration and allows improved blocking of PD-L1 at the tumor site

Jingjing Zhu

Jingjing Zhu, Senior Research Scientist, Ludwig Institute for Cancer Research

 13:45 - 14:15

Nanopore technology - transforming genomics and transcriptomics

Miten Jain

Miten Jain, Assistant Research Scientist, University of California Santa Cruz

 14:15 - 14:45

Closing Remarks from the Chairman

 14:45 - 14:50

Networking and One-on-One Meetings

 14:50 - 16:00

SPEAKERS

Shashi Ramaiah

Shashi Ramaiah

Head, Safety Biomarkers, Translational Sciences, Pfizer

Paul Keown

Paul Keown

Professor of Medicine, University of British Columbia

Maria Orr

Maria Orr

Head of Precision Medicine, AstraZeneca

Yinghui Zhou

Yinghui Zhou

Senior Director, Translational Strategy, Bayer

Chetan Deshpande

Chetan Deshpande

Biomarker Operations Lead, Pfizer

Jim Christian

Jim Christian

Pathologist, Companion Diagnostics, Agilent Technologies

Jijumon Chelliserry

Jijumon Chelliserry

Senior Manager, Biomarker Clinical Assay Lead, Pfizer

Mark Verardo

Mark Verardo

Senior Scientific Program Manager, Agilent Technologies, USA

Matt Davis

Matt Davis

Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

Elizabeth Crone

Elizabeth Crone

Business Development Manager, Owlstone Medical

Jason Kinchen

Jason Kinchen

Lead Biomarker Discovery Scientist, Owlstone Medical

Hillary Sloane

Hillary Sloane

Associate Director, Medical Scientific Affairs, Sysmex Inostics

Miten Jain

Miten Jain

Assistant Research Scientist, University of California Santa Cruz

Reny Aniline

Reny Aniline

MBA Senior Director, BioPharma Business Development, Natera

Angel Augusto Rodriguez

Angel Augusto Rodriguez

Oncoloy Medical Director, Natera

Jim Garrett

Jim Garrett

Senior Associate Director Biostatistics, Novartis

James Yen

James Yen

Associate Director, CDx Strategy, , NeoGenomics

George Weiner

George Weiner

Oncologist, University of Iowa

Jessica McDonough

Jessica McDonough

Co-Founder, Attivare Therapeutics

George Pell

George Pell

CEO and Founder, Thirty-Six

Karen Sherwood

Karen Sherwood

Director of Scientific Programs, Lead scientist, Genome Canada Transplant Consortium

Pallavi Sachdev

Pallavi Sachdev

Senior Director, Clinical Pharmacology and Translational Medicine , Eisai

Barbara Cahill

Barbara Cahill

Sr. Global Portfolio Manager for Immunohistochemistry, Consumables and Cytology, , Epredia

Reed Selby

Reed Selby

Director of Biopharma Business Development, Predicine

Marion Cubitt

Marion Cubitt

Associate Director, Isogenica

Stefan Pinkert

Stefan Pinkert

Principal Scientist, Oncology Bioinformatics, Merck

Donald Atha

Donald Atha

Research Chemist, National Institute of Standards and Technology (NIST)

Jingjing Zhu

Jingjing Zhu

Senior Research Scientist, Ludwig Institute for Cancer Research

Stephen Pennington

Stephen Pennington

Professor, Proteomics, University College Dublin

Ibrahim Jivanjee

Ibrahim Jivanjee

Director of Product Management and Marketing, Arima Genomics

Pamela Pulimeno

Pamela Pulimeno

Scientific Project Manager and Scientific Communication, Lunaphore

SPONSORS

Agilent
Natera
Proteome Sciences
Owlstone Medical
NeoGenomics
Sysmex
PHC Group
Predicine
Arima Genomics

PARTNERS

Georgia Bio
PharmaVOICE
Pharma Journalist
HealthEconomics.Com
This Week in Digital Health
The Journal of mHealth
IDDB Journal

24/7 Customer Support

Asia Office

Phone : +91 20 48598285
[email protected]

USA Office

Phone : +1-888600-6441
[email protected]